Viral arthritis and COVID-19
S Parisi, R Borrelli, S Bianchi, E Fusaro - The Lancet Rheumatology, 2020 - thelancet.com
The current outbreak of COVID19, caused by severe acute respiratory syndrome
coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as …
coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as …
[PDF][PDF] Immunosuppression for hyperinflammation in COVID-19: a double-edged sword
AI Ritchie, A Singanayagam - Lancet, 2020 - udruzenjepedijatara.rs
Mehta and colleagues1 postulate that hyperinflammation in coronavirus disease 2019
(COVID-19) could be a driver of severity that is amenable to therapeutic targeting since …
(COVID-19) could be a driver of severity that is amenable to therapeutic targeting since …
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
[HTML][HTML] IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study
M Franzetti, A Forastieri, N Borsa… - The Journal of …, 2021 - journals.aai.org
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
[引用][C] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
X Mariette, O Hermine… - LANCET …, 2021 - ELSEVIER SCI LTD THE …
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
C Garbers, S Rose-John - The Lancet Rheumatology, 2021 - thelancet.com
CG has received a research grant from Corvidia Therapeutics and has acted as a consultant
for AbbVie. SRJ has acted as a consultant and speaker for AbbVie, Chugai, Roche …
for AbbVie. SRJ has acted as a consultant and speaker for AbbVie, Chugai, Roche …
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
G Bozzi, D Mangioni, F Minoia, S Aliberti… - Journal of Allergy and …, 2021 - Elsevier
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
E Iglesias-Julián, M López-Veloso… - Journal of …, 2020 - Elsevier
Objective Severely ill COVID-19 patients may end in acute respiratory distress syndrome
(ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state …
(ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state …
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
RH Haberman, S Um, JE Axelrad, RB Blank… - The Lancet …, 2022 - thelancet.com
Studies have revealed that patients with immunemediated inflammatory diseases, especially
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
Rheumatology and COVID-19 at 1 year: facing the unknowns
L Calabrese, KL Winthrop - Annals of the rheumatic diseases, 2021 - ard.bmj.com
Diseases includes the freshly minted European Alliance of Associations for Rheumatology
(EULAR) points to consider on the pathophysiology and use of immunomodulatory therapies …
(EULAR) points to consider on the pathophysiology and use of immunomodulatory therapies …